rabies vaccine (Rx)

Brand and Other Names:HDCV, Imovax Rabies, more...rabies vaccine human diploid cell culture
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, freeze-dried suspension

  • ≥2.5 IU/mL

Rabies Preexposure Immunization

Primary

  • 1 mL IM (deltoid region) x3 doses
  • Administer on days 0, 7, and 21 or 28

Booster

  • 1 mL IM (deltoid region) to maintain a serum titer >1:5 serum dilution by RFFIT

Frequency for testing serum titers

  • Continuous risk
    • Test serum for rabies antibodies q6month in persons working with live rabies virus in research laboratories and in vaccine production facilities (continuous risk category)
  • Frequent risk
    • Other laboratory workers (eg, those performing rabies diagnostic testing), cavers, veterinarians and staff, animal-control and wildlife officers in areas where rabies is enzootic, and bat handlers regardless of location
    • If titer inadequate, administer single booster dose of vaccine
  • Infrequent risk
    • Veterinarians, veterinary students, and terrestrial animal-control and wildlife officers, working in areas of low rabies endemicity and certain at-risk international travelers who have completed a full preexposure vaccination series with licensed vaccines and according to schedule do not require routine booster serologic verification of detectable antibody titers or routine preexposure booster doses of vaccine

Rabies Postexposure Immunization

Unimmunized individuals

  • 1 mL IM x5 doses
  • Administer on days 0, 3, 7, 14, and 28 in conjunction with administration of human rabies immune globulin (HRIG) on day 0
  • HRIG: 20 IU/kg; if anatomically feasible, the full dose should be infiltrated around and into the wound(s), and any remaining volume should be administered IM at an anatomical site distant from vaccine administration

Previously immunized individuals

  • 1 mL IM x2 doses on days 0 and 3

Additional Information

Current vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.html

Dosage Forms & Strengths

injection, freeze-dried suspension

  • ≥2.5 IU/mL

Rabies Preexposure Immunization

Vaccination is recommended for children living in or visiting countries where exposure to rabid animals is a constant threat; worldwide statistics indicate children are more at risk than adults

Primary

  • 1 mL IM (deltoid region, in small children and infants anterolateral region of thigh) x3 doses
  • Administer on days 0, 7, and 21 or 28

Booster

  • 1 mL IM (deltoid region) to maintain a serum titer >1:5 serum dilution by RFFIT

Frequency for testing serum titers

  • Continuous risk
    • Test serum for rabies antibodies q6month in persons working with live rabies virus in research laboratories and in vaccine production facilities (continuous risk category)
  • Frequent risk
    • Other laboratory workers (eg, those performing rabies diagnostic testing), cavers, veterinarians and staff, animal-control and wildlife officers in areas where rabies is enzootic, and bat handlers regardless of location
    • If titer inadequate, administer single booster dose of vaccine
  • Infrequent risk
    • Veterinarians, veterinary students, and terrestrial animal-control and wildlife officers, working in areas of low rabies endemicity and certain at-risk international travelers who have completed a full preexposure vaccination series with licensed vaccines and according to schedule do not require routine booster serologic verification of detectable antibody titers or routine preexposure booster doses of vaccine

Rabies Postexposure Immunization

Unimmunized individuals

  • 1 mL IM x5 doses
  • Administer on days 0, 3, 7, 14, and 28 in conjunction with administration of human rabies immune globulin (HRIG) on day 0
  • HRIG: 20 IU/kg; if anatomically feasible, the full dose should be infiltrated around and into the wound(s), and any remaining volume should be administered IM at an anatomical site distant from vaccine administration

Previously immunized individuals

  • 1 mL IM x2 doses on days 0 and 3

Additional Information

Current vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.html

Next:

Interactions

Interaction Checker

and rabies vaccine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (1)

            • belimumab

              belimumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab.

            Serious - Use Alternative (36)

            • adalimumab

              adalimumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • alefacept

              alefacept decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • anakinra

              anakinra decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • antithymocyte globulin equine

              antithymocyte globulin equine decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • antithymocyte globulin rabbit

              antithymocyte globulin rabbit decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • azathioprine

              azathioprine decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • basiliximab

              basiliximab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • budesonide

              budesonide decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • canakinumab

              canakinumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressant may interfere with development of active immunity.

            • cortisone

              cortisone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • deflazacort

              deflazacort decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • dexamethasone

              dexamethasone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • etanercept

              etanercept decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • everolimus

              everolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • fludrocortisone

              fludrocortisone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • glatiramer

              glatiramer decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • golimumab

              golimumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • hydrocortisone

              hydrocortisone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • hydroxychloroquine sulfate

              hydroxychloroquine sulfate decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • infliximab

              infliximab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • leflunomide

              leflunomide decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • methylprednisolone

              methylprednisolone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • muromonab CD3

              muromonab CD3 decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • mycophenolate

              mycophenolate decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • ocrelizumab

              ocrelizumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live-attenuated or live vaccines is not recommended during ocrelizumab treatment and until B-cell repletion.

            • ofatumumab SC

              ofatumumab SC decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible.

            • prednisolone

              prednisolone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • prednisone

              prednisone decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Corticosteroids may interfere with development of active immunity.

            • rilonacept

              rilonacept decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • secukinumab

              secukinumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating secukinumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with secukinumab may not elicit an immune response sufficient to prevent disease.

            • siponimod

              siponimod decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk.

            • sirolimus

              sirolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • tacrolimus

              tacrolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • temsirolimus

              temsirolimus decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • tocilizumab

              tocilizumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            • triamcinolone acetonide injectable suspension

              triamcinolone acetonide injectable suspension decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.

            Monitor Closely (17)

            • certolizumab pegol

              certolizumab pegol decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor.

            • cyclosporine

              cyclosporine decreases effects of rabies vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). .

            • ibrutinib

              ibrutinib decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .

            • ifosfamide

              ifosfamide decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .

            • lomustine

              lomustine decreases effects of rabies vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .

            • mechlorethamine

              mechlorethamine decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .

            • melphalan

              melphalan decreases effects of rabies vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .

            • mercaptopurine

              mercaptopurine decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressants may interfere with development of active immunity.

            • methotrexate

              methotrexate decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Concomitant administration of methotrexate can decrease the immunological response of vaccines.

            • onasemnogene abeparvovec

              onasemnogene abeparvovec decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. When initiating systemic corticosteriod therapy, wait 2 weeks after an inactivated vaccine.

            • oxaliplatin

              oxaliplatin decreases effects of rabies vaccine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .

            • ponesimod

              ponesimod decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. If possible, complete all age-appropriate vaccinations at least 4 weeks before initiating ponesimod.

            • procarbazine

              procarbazine decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. .

            • rabies immune globulin, human (RIG)

              rabies immune globulin, human (RIG) decreases effects of rabies vaccine by Other (see comment). Use Caution/Monitor. Comment: RIG may be administered concurrently with and up to 8 days after rabies vaccine. High dose rabies immunoglobulin may impair response to active immunization. .

            • rituximab

              rituximab, rabies vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab.

            • rituximab-hyaluronidase

              rituximab-hyaluronidase, rabies vaccine. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab.

            • ustekinumab

              ustekinumab decreases effects of rabies vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Inactivated vaccinations administered during ustekinumab treatment may not elicit an immune response sufficient to prevent disease.

            Minor (2)

            • chloroquine

              chloroquine decreases effects of rabies vaccine by pharmacodynamic antagonism. Minor/Significance Unknown. Immunosuppressants may interfere with development of active immunity.

            • ozanimod

              ozanimod decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Minor/Significance Unknown. No clinical data are available on the efficacy and safety of vaccinations in patients taking ozanimod. Vaccinations may be less effective if coadministered with ozanimod.

            Previous
            Next:

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), submit an online report at https://vaers.hhs.gov/reportevent.html or call 1-800-822-7967

            >10%

            Injection site reactions (eg, pain, erythema, swelling or itching) (25%)

            Headache (20%)

            Nausea (20%)

            Abdominal pain (20%)

            Muscle aches (20%)

            Dizziness (20%)

            1-10%

            Serum sickness (7%)

            Postmarketing Reports

            Blood and lymphatic system disorders: Lymphadenopathy

            Immune system disorders: Anaphylactic reaction, serum sickness type reaction, dermatitis allergic, pruritus (itching), edema

            Nervous system disorders: Paresthesia, neuropathy, convulsion, encephalitis, Guillain-Barré-like syndrome

            Gastrointestinal disorders: Vomiting, diarrhea

            Musculoskeletal and connective tissue disorders: Arthralgia

            General disorders and administration site conditions: Asthenia, malaise, fever and chills (shivering), injection site hematoma

            Respiratory, thoracic, and mediastinal disorders: Wheezing, dyspnea

            Previous
            Next:

            Warnings

            Contraindications

            Preexposure prophylaxis

            • Known life-threatening hypersensitivity to vaccine, neomycin, or any component of a vaccine

            Postexposure prophylaxis

            • None

            Cautions

            When dose must be administered to person with history of hypersensitivity, antihistamines may be given; have epinephrine (1:1000) and other appropriate agents readily available to counteract anaphylactic reactions while carefully monitoring after immunization

            Serum sickness type reactions reported in persons receiving booster doses for preexposure prophylaxis; characterized by onset ~2-21 days post-booster, presents with a generalized urticaria, and may also include arthralgia, arthritis, angioedema, nausea, vomiting, fever, and malaise

            Rare cases of neurologic illness resembling Guillain-Barré-like syndrome have occurred

            Product contains albumin; remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD)

            Immunosuppressive illnesses can interfere with vaccine efficacy

            Drug interaction overview

            • Immunosuppressive drugs
              • Corticosteroids or other immunosuppressive can interfere with the development of active immunity and predispose the patient to developing rabies
              • Do not administer immunosuppressive agents during postexposure therapy, unless essential for the treatment of other conditions
              • When rabies postexposure prophylaxis is administered to persons receiving steroids or other immunosuppressive therapy, test for rabies antibody to ensure that an adequate response has developed
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Preexposure

            • Animal reproduction studies have not been conducted
            • It is also not known whether rabies vaccine can cause fetal harm when administered to pregnant women or can affect reproductive capacity
            • Administer to pregnant women only if potential benefits outweigh potential risks
            • If there is substantial risk of exposure to rabies, preexposure prophylaxis may also be indicated during pregnancy

            Postexposure

            • Because of the potential consequences of inadequately treated rabies exposure and limited data that indicate that fetal abnormalities have not been associated with rabies vaccination, pregnancy is not considered a contraindication to postexposure prophylaxis

            Lactation

            Unknown if excreted in human milk; exercise caution

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Inactivated virus vaccine provides immunity to rabies by eliciting an active immune response

            Pharmacokinetics

            Onset (antibodies): 7-10 days

            Duration (antibodies): >1 year

            Peak Plasma Time (antibodies): 30-60 days

            Previous
            Next:

            Administration

            IM Preparation

            Using the longer of the 2 needles supplied, transfer the entire contents of provided diluent into vaccine vial to reconstitute the freeze-dried vaccine

            Mix gently to avoid foaming

            The creamy white to orange freeze-dried vaccine dissolves to a pink-to-red suspension

            Withdraw total amount of dissolved vaccine into the syringe and replace long needle with smaller needle for IM injection

            IM Administration

            Adults and older children: Inject IM in deltoid muscle

            Infants and small children: Inject IM in anterolateral aspect of the thigh

            Do not inject in gluteal area; may result in lower neutralizing antibody titers

            Storage

            Refrigerate at 2-8ºC (35-46ºF)

            Do not freeze

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            Imovax Rabies Vaccine (PF) intramuscular
            -
            2.5 unit vial

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Patient Education
            rabies vaccine,human diploid (PF) intramuscular

            NO MONOGRAPH AVAILABLE AT THIS TIME

            USES: Consult your pharmacist.

            HOW TO USE: Consult your pharmacist.

            SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Consult your pharmacist.

            DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

            NOTES: No monograph available at this time.

            MISSED DOSE: Consult your pharmacist.

            STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

            Information last revised July 2016. Copyright(c) 2021 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.